Researchers have discovered that a person's "bioenergetic age," reflecting how efficiently cells produce energy, strongly ...

Scientists have discovered that how well a person’s cells generate energy—what they call “bioenergetic age”—could be a strong ...

▎药明康德内容团队编辑卫材（Eisai）和渤健（Biogen）日前宣布，欧洲药品管理局（EMA）人用药品委员会（CHMP）已再度确认对其联合开发的阿尔茨海默病（AD）疗法Leqembi（lecanemab）的积极意见，推荐它用于治疗确诊为阿尔茨海默病 ...

Bioenergetic age, or how efficiently cells produce energy, could predict Alzheimer’s risk, with healthy lifestyle choices ...

A person's "bioenergetic age"—or how youthfully their cells generate energy—might be a key indicator of whether they're at ...

Spatial transcriptomics on human brains parsed microglial reactions to amyloid immunotherapy. Both a vaccine and a therapeutic antibody summoned these cells to plaques. Responders expressed TREM2, ...

The National Institute for Health and Care Excellence (NICE) has decided to reconsult on draft guidance for Alzheimer’s treatments donanemab and lecanemab, six months after initially rejecting the ...

While researchers continue to work on a full cure for Alzheimer's disease, they're finding treatments that can help manage ...

Chicago area scientists have identified the genes that drive the process of Alzheimer's disease and are working to make the drug Lecanemab even better by identifying which genes are active in the ...

NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs ...

Eisai remains committed to ensuring eligible Australians with early Alzheimer's disease can access lecanemab and is exploring options to achieve this, including potentially seeking review by the ...